Methylphenidate Viatris

Methylphenidate hydrochloride, the active ingredient in Methylphenidate Viatris, is a central nervous system stimulant presented as an oral tablet for oral use. It is prescribed to manage symptoms of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidate Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides regulatory‑compliant documentation for cross‑border shipments.

Methylphenidate acts on central nervous system pathways involved in attention and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity, helping patients achieve better academic and occupational performance. - Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes, allowing more stable daily functioning and reduced risk of accidents.

Methylphenidate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain or nausea: gastrointestinal discomfort. - Irritability or mood swings. - Weight loss: especially in pediatric patients.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmias. - Psychosis or severe agitation. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Motor or vocal tics. - Growth suppression in children. - Seizures: particularly in predisposed individuals.

Before prescribing methylphenidate, clinicians should evaluate several safety considerations.

- Assess cardiovascular status: obtain baseline blood pressure and heart rate before initiating therapy. - Monitor growth in children: track height and weight regularly during treatment. - Avoid use in patients with known hypersensitivity to methylphenidate or its excipients. - Use caution with concomitant antidepressants: increased risk of serotonin syndrome. - Educate about abuse potential: schedule II controlled substance requires strict monitoring. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Methylphenidate can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: may reduce efficacy of blood pressure control. - Other CNS stimulants: additive sympathomimetic effects.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): monitor for serotonin syndrome. - Antipsychotics: may diminish methylphenidate's therapeutic effect. - Alcohol: can potentiate central nervous system depression and increase side‑effect burden.